Concepedia

Shenglei Li

SL

13

Publications

403

Citations

13

H-Index

2007

Active since

Affiliations

First Affiliated Hospital of Zhengzhou University(Current)

Zhengzhou University

Soochow University

Nanyang Institute of Technology

Jiangsu Hengrui Medicine (China)

Shenglei Li is an author at First Affiliated Hospital of Zhengzhou University specializing in medicine, pathology, and tumor biology.

Top concepts

MedicinePathologyOncologyCell BiologyTumor BiologyCancer ResearchRadiation OncologyTumor MicroenvironmentGene ExpressionGenetics

Publications per year

2007–2024

13

Publications

13

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

Xiangrui Meng, Tao Wu, Yonggui Hong et al. · The Lancet. Gastroenterology & hepatology · 2022 · 82 citations

Second-line Treatment, Oncology, Esophageal Cancer +6

Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion

Shi Guanghui, Yifei Cheng, Yang Zhang et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2020 · 59 citations

Cancer Proliferation, Long Non-coding Rna, Breast Cancer +6

Clinical characteristics and prognostic analysis of <scp>SMARCA4</scp>‐deficient non‐small cell lung cancer

Xiyue Liang, Xianzheng Gao, Feng Wang et al. · Cancer Medicine · 2023 · 48 citations · Full text

Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma

Shenglei Li · World Journal of Gastroenterology · 2007 · 42 citations · Full text

RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma

Zhaoming Lu, Xiaojing Shi, Fanghua Gong et al. · Acta Pharmaceutica Sinica B · 2020 · 30 citations · Full text

Rows per page

1–5 of 13